Chembio Diagnostics Stock Price, News & Analysis (NASDAQ:CEMI)

$7.60 -0.10 (-1.30 %)
(As of 02/19/2018 12:54 PM ET)
Previous Close$7.70
Today's Range$7.55 - $7.80
52-Week Range$5.05 - $9.20
Volume69,000 shs
Average Volume36,058 shs
Market Capitalization$107.74 million
P/E Ratio-13.33
Dividend YieldN/A
Beta1.14

About Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic & Testing Substances Manufacturers
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Debt-to-Equity Ratio0.01%
Current Ratio3.54%
Quick Ratio2.19%

Price-To-Earnings

Trailing P/E Ratio-13.3333333333333
Forward P/E Ratio-15.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.87 million
Price / Sales6.03
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book5.31

Profitability

Trailing EPS($0.57)
Net Income$-13,340,000.00
Net Margins-32.42%
Return on Equity-42.76%
Return on Assets-34.54%

Miscellaneous

Employees131
Outstanding Shares14,180,000

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) released its quarterly earnings data on Thursday, August, 11th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.75. The firm earned $3.27 million during the quarter, compared to the consensus estimate of $6.72 million. Chembio Diagnostics had a negative net margin of 32.42% and a negative return on equity of 42.76%. View Chembio Diagnostics' Earnings History.

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:

  • John J. Sperzel III, President, Chief Executive Officer, Director (Age 52)
  • Neil A. Goldman, Chief Financial Officer, Executive Vice President
  • Sharon Klugewicz, President - Americas Region (Age 49)
  • Javan Esfandiari, Chief Science and Technology Officer (Age 48)
  • Tom Ippolito, Vice President - Regulatory Affairs, Quality Assurance and Quality Control (Age 52)
  • Paul Lambotte Ph.D., Vice President - Product Development (Age 64)
  • Michael K. Steele, Vice President - Business Development, Sales and Marketing (Age 48)
  • Katherine L. Davis, Non-Executive Independent Chairman of the Board (Age 58)
  • Gail S. Page, Director
  • Peter T. Kissinger Ph.D., Independent Director (Age 70)

Who owns Chembio Diagnostics stock?

Chembio Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional investors include Royce & Associates LP (0.83%), Benchmark Capital Advisors (0.54%) and Perkins Capital Management Inc. (0.21%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Neil A Goldman, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.

Who sold Chembio Diagnostics stock? Who is selling Chembio Diagnostics stock?

Chembio Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Chembio Diagnostics.

Who bought Chembio Diagnostics stock? Who is buying Chembio Diagnostics stock?

Chembio Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP and Benchmark Capital Advisors. Company insiders that have bought Chembio Diagnostics stock in the last two years include Neil A Goldman and Norman H Pessin. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy Chembio Diagnostics stock?

Shares of Chembio Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of Chembio Diagnostics stock can currently be purchased for approximately $7.60.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $107.74 million and generates $17.87 million in revenue each year. The company earns $-13,340,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Chembio Diagnostics employs 131 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (CEMI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chembio Diagnostics (NASDAQ:CEMI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$9.00
Price Target Upside: N/AN/AN/A34.33% upside

Chembio Diagnostics (NASDAQ:CEMI) Consensus Price Target History

Price Target History for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ:CEMI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2016BenchmarkSet Price TargetBuy$9.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Chembio Diagnostics (NASDAQ:CEMI) Earnings History and Estimates Chart

Earnings by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ CEMI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.11)($0.05)$5.65 million$7.59 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.17)($0.18)$4.96 million$2.89 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.20)($0.13)$4.88 million$5.43 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.15)($0.21)$4.44 million$4.26 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.17)($0.19)$3.76 million$3.75 millionViewN/AView Earnings Details
8/11/2016Q2($0.11)($0.86)$6.72 million$3.27 millionViewListenView Earnings Details
5/12/2016Q1($0.09)($0.03)$4.83 million$6.60 millionViewListenView Earnings Details
3/8/2016Q4($0.09)($0.07)$6.56 million$4.42 millionViewN/AView Earnings Details
11/12/2015Q3($0.09)($0.05)$6.77 million$6.89 millionViewListenView Earnings Details
8/6/2015Q2($0.03)($0.07)$7.53 million$6.72 millionViewN/AView Earnings Details
5/7/2015Q115($0.08)($0.07)$5.20 million$6.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.04)($0.05)$7.10 million$7.10 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.03)($0.03)$7.71 million$7.31 millionViewN/AView Earnings Details
8/7/2014Q2($0.02)($0.02)$6.25 million$7.42 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.02)($0.02)$6.87 million$5.81 millionViewN/AView Earnings Details
3/6/2014Q413$0.04($0.03)$7.05 million$7.86 millionViewN/AView Earnings Details
11/7/2013Q3 2013$0.06$0.07$8.59 million$9.62 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.04)($0.03)$5.56 million$5.39 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.06$0.04$7.47 million$6.31 millionViewN/AView Earnings Details
3/7/2013Q4 2012$0.07$0.06ViewN/AView Earnings Details
11/13/2012Q312$0.04($0.04)$6.11 million$5.01 millionViewN/AView Earnings Details
8/9/2012$0.05$0.04ViewN/AView Earnings Details
5/8/2012Q1 2012$0.08$0.05ViewN/AView Earnings Details
3/8/2012Q4 2011$0.08$0.06ViewN/AView Earnings Details
11/3/2011Q3 2011$0.06ViewN/AView Earnings Details
8/4/2011Q2 2011$0.02ViewN/AView Earnings Details
5/5/2011Q1 2011($0.02)ViewN/AView Earnings Details
3/3/2011Q4 2010$0.22ViewN/AView Earnings Details
11/4/2010Q3 2010$0.02ViewN/AView Earnings Details
7/29/2010Q2 2010($0.08)$0.07ViewN/AView Earnings Details
5/6/2010Q1 2010($0.02)ViewN/AView Earnings Details
3/5/2010Q4 2009$0.02ViewN/AView Earnings Details
11/4/2009Q3 2009$0.03ViewN/AView Earnings Details
5/8/2009Q1 2009($0.08)ViewN/AView Earnings Details
11/12/2008Q3 2008($0.08)($0.03)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.08)($0.08)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.80)($2.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Chembio Diagnostics (NASDAQ:CEMI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.48 EPS
Next Year EPS Consensus Estimate: $-0.21 EPS

Dividends

Dividend History for Chembio Diagnostics (NASDAQ:CEMI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Chembio Diagnostics (NASDAQ CEMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.56%
Institutional Ownership Percentage: 30.66%
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ:CEMI)
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Chembio Diagnostics (NASDAQ CEMI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Neil A GoldmanCFOBuy14,815$6.75$100,001.2514,815View SEC Filing  
6/28/2017Norman H PessinInsiderBuy36,250$5.48$198,650.00View SEC Filing  
6/15/2016Sharon W KlugewiczCOOSell3,000$8.40$25,200.007,000View SEC Filing  
6/1/2016Javan EsfandiariInsiderSell25,000$8.58$214,500.0079,110View SEC Filing  
5/29/2015Javan EsfandiariInsiderSell20,000$4.50$90,000.00View SEC Filing  
11/19/2014Peter KissingerDirectorBuy1,800$4.31$7,758.00View SEC Filing  
2/26/2014Sharon W KlugewiczCOOBuy10,000$3.50$35,000.00View SEC Filing  
12/6/2013Javan EsfandiariSVPSell10,000$3.40$34,000.00View SEC Filing  
11/11/2013Lawrence A SiebertMajor ShareholderSell30,000$3.63$108,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chembio Diagnostics (NASDAQ CEMI) News Headlines

Source:
DateHeadline
Neil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) StockNeil A. Goldman Purchases 14,815 Shares of Chembio Diagnostics Inc (CEMI) Stock
www.americanbankingnews.com - February 13 at 3:18 PM
Chembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/ShChembio Diagnostics (CEMI) Prices 1.78M Share Common Offering at $6.75/Sh
www.streetinsider.com - February 10 at 8:57 AM
Chembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial ResultsChembio Diagnostics Announces Major New Tender Win and Certain Preliminary 2017 Financial Results
finance.yahoo.com - February 9 at 9:05 AM
Chembio Diagnostics Announces Proposed Public Offering of Common StockChembio Diagnostics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 9 at 9:05 AM
Chembio Diagnostics Announces Pricing of its Public Offering of Common StockChembio Diagnostics Announces Pricing of its Public Offering of Common Stock
finance.yahoo.com - February 9 at 9:05 AM
ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017ETFs with exposure to Chembio Diagnostics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:57 PM
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:55 PM
Chembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial OfficerChembio Diagnostics (CEMI) Names Neil A. Goldman as Chief Financial Officer
www.streetinsider.com - December 21 at 5:25 PM
Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis SystemChembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System
finance.yahoo.com - December 21 at 9:23 AM
Chembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial OfficerChembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial Officer
finance.yahoo.com - December 20 at 9:25 AM
Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic TestChembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test
www.nasdaq.com - December 19 at 9:24 AM
Chembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic TestChembio Diagnostics and AstraZeneca Enter a Collaboration to Develop Point-of-Care Diagnostic Test
finance.yahoo.com - December 19 at 9:24 AM
Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.s FY2018 Earnings (CEMI)Zacks Investment Research Weighs in on Chembio Diagnostics, Inc.'s FY2018 Earnings (CEMI)
www.americanbankingnews.com - December 11 at 10:50 AM
CEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple ExpansionCEMI: Moving PT to $15.5/Share On Upward Revenue Revisions, Comp Multiple Expansion
finance.yahoo.com - December 7 at 5:53 PM
Chembio Receives $4.2 Million in Accounts Receivable Payments from Bio-ManguinhosChembio Receives $4.2 Million in Accounts Receivable Payments from Bio-Manguinhos
www.nasdaq.com - December 6 at 9:33 AM
Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018Chembio Diagnostics (CEMI) Secures $8.5M Commitment from Bio-Manguinhos to Purchase Components for Production of DPP Assays in 2018
www.streetinsider.com - December 6 at 9:33 AM
Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018
finance.yahoo.com - December 5 at 10:04 AM
CEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 GrowthCEMI: DPP HIV/Syph, Several DPP Fever Products to Drive 2018 Growth
finance.yahoo.com - November 20 at 6:13 PM
Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 7:55 PM
ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 7:55 PM
CHEMBIO DIAGNOSTICS, INC. to Host Earnings CallCHEMBIO DIAGNOSTICS, INC. to Host Earnings Call
finance.yahoo.com - November 8 at 8:42 PM
Chembio Diagnostics Reports Third Quarter 2017 Financial ResultsChembio Diagnostics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 8:42 PM
Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017
finance.yahoo.com - November 7 at 8:03 PM
Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial ResultsChembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results
feeds.benzinga.com - November 1 at 9:28 AM
ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 3:41 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 5:50 PM
ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 11:39 AM
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 12:24 PM
Chembio Announces Return of President and CEO John SperzelChembio Announces Return of President and CEO John Sperzel
www.nasdaq.com - October 3 at 2:13 AM
Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM TestChembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test
finance.yahoo.com - October 2 at 4:09 PM
BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31
www.reuters.com - August 17 at 11:24 PM
Chembio Diagnostics (CEMI) CFO to RetireChembio Diagnostics (CEMI) CFO to Retire
www.streetinsider.com - August 17 at 6:23 PM
Chembio Diagnostics Announces Retirement of Chief Financial OfficerChembio Diagnostics Announces Retirement of Chief Financial Officer
finance.yahoo.com - August 17 at 6:23 PM
Chembio Diagnostics (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call TranscriptChembio Diagnostics' (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 5:29 PM
Chembio Diagnostics, Inc. (CEMI) Posts  Earnings Results, Misses Expectations By $0.02 EPSChembio Diagnostics, Inc. (CEMI) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 9:28 PM
Edited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:15 PM
Chembio Diagnostics Reports Second Quarter 2017 Financial ResultsChembio Diagnostics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:16 PM
Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017
finance.yahoo.com - August 8 at 4:49 PM
Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial ResultsChembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:35 PM
Gail S. Page Joins Chembio Diagnostics Board of DirectorsGail S. Page Joins Chembio Diagnostics Board of Directors
finance.yahoo.com - July 6 at 6:19 PM
Chembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory AgencyChembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory Agency
www.streetinsider.com - July 5 at 10:53 PM
Chembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory AgencyChembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory Agency
finance.yahoo.com - July 5 at 5:49 PM
Chembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market ProgramChembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market Program
www.streetinsider.com - June 27 at 9:31 PM
Chembio Diagnostics (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call TranscriptChembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:24 PM
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual ReportCHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 4:16 PM
Q4 2016 Chembio Diagnostics Inc Earnings Release - After Market CloseQ4 2016 Chembio Diagnostics Inc Earnings Release - After Market Close
biz.yahoo.com - March 7 at 12:28 PM
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsCHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 28 at 4:27 PM
Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27
www.streetinsider.com - January 29 at 2:25 AM
ADHD Doesnt MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed StudyADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study
www.rttnews.com - January 18 at 3:03 AM
2:06 pm Chembio Diagnostics amends the terms of its previously announced stock purchase agreement with RVR Diagnostics2:06 pm Chembio Diagnostics amends the terms of its previously announced stock purchase agreement with RVR Diagnostics
us.rd.yahoo.com - December 13 at 4:53 PM

SEC Filings

Chembio Diagnostics (NASDAQ:CEMI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chembio Diagnostics (NASDAQ:CEMI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chembio Diagnostics (NASDAQ CEMI) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.